Abstract
Aberrant Wnt signaling, mainly through mutations of APC and in some cases of CTNNB1 or AXIN2, has been found in the majority of colorectal cancers. Recently, frequent promoter hypermethylation was identified to cause silencing of the secreted frizzled-related protein (sFRP) family in colorectal cancer. Restoration of sFRP in colorectal cancer cells attenuates Wnt signaling even in the presence of downstream mutations. Here we show that Wnt inhibitory factor-1 (WIF-1), a different secreted antagonist of Wnt signaling, is also silenced by promoter hypermethylation in colorectal cancer cells. Restoration of WIF-1 function, Wnt-1 siRNA, or a monoclonal anti-Wnt-1 antibody that we developed attenuates Wnt-1 signaling and induces significant apoptosis in these cells containing downstream mutations and expressing Wnt-1. In addition, this monoclonal anti-Wnt-1 antibody showed synergistic effects with docetaxel in treating these colorectal cancer cells and great efficacy in treating primary colorectal cancer cultures freshly prepared from patients. Therefore, our data support the hypothesis that constitutive Wnt signaling may be required to complement downstream mutations in the evolution of colorectal cancer. Furthermore, our results suggest that blockade of the Wnt signal may have a therapeutic role in the treatment of colorectal cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F . (1991). Cancer Res, 51, 4845–4852.
Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM and Morton DG . (2004). Cancer Res., 64, 883–888.
Ciani L, Krylova O, Smalley MJ, Dale TC and Salinas PC . (2004). J. Cell Biol., 164, 243–253.
Clark TB, Kemeny NE, Conti JA, Huang Y, Andre AM and Stockman J . (1998). Cancer Invest., 16, 314–318.
Dimitriadis A, Vincan E, Mohammed IM, Roczo N, Phillips WA and Baindur-Hudson S . (2001). Cancer Lett., 166, 185–191.
Dunne AL, Mothersill C, Robson T, Wilson GD and Hirst DG . (2004). Oncol. Res., 14, 447–454.
Elbashir SM, Harborth J, Weber K and Tuschl T . (2002). Methods, 26, 199–213.
Fodde R, Smits R and Clevers H . (2001). Nat. Rev. Cancer, 1, 55–67.
Giles RH, van Es JH and Clevers H . (2003). Biochim. Biophys. Acta, 1653, 1–24.
He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F and Jablons DM . (2004). Neoplasia, 6, 7–14.
He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F and Jablons DM . (2003). Proc. Natl. Acad. Sci. USA, 100, 14133–14138.
Heighway J, Knapp T, Boyce L, Brennand S, Field JK, Betticher DC, Ratschiller D, Gugger M, Donovan M, Lasek A and Rickert P . (2002). Oncogene, 21, 7749–7763.
Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T and Truong T . (2002). Mol. Pathol., 55, 220–226.
Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB and Nathans J . (1999). Nature, 398, 431–436.
Karantanis E, Nicholson S and Morris DL . (1994). Eur. J. Surg. Oncol., 20, 653–657.
Kawano Y and Kypta R . (2003). J. Cell Sci., 116, 2627–2634.
Kim PJ, Plescia J, Clevers H, Fearon ER and Altieri DC . (2003). Lancet, 362, 205–209.
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H . (1997). Science, 275, 1784–1787.
Lin K, Wang S, Julius MA, Kitajewski J, Moos Jr M and Luyten FP . (1997). Proc. Natl. Acad. Sci. USA, 94, 11196–11200.
Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI and Thibodeau SN . (2000). Nat. Genet., 26, 146–147.
Mazieres J, He B, You L, Xu Z, Lee A, Mikami I, Reguart N, Rosell R, McCormick F and Jablons DM . (2004). Cancer Res., 64, 4717–4720.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW . (1997). Science, 275, 1787–1790.
Smith K, Bui TD, Poulsom R, Kaklamanis L, Williams G and Harris AL . (1999). Br. J. Cancer, 81, 496–502.
Sternberg CN, ten Bokkel Huinink WW, Smyth JF, Bruntsch V, Dirix LY, Pavlidis NA, Franklin H, Wanders S, Le Bail N and Kaye SB . (1994). Br. J. Cancer, 70, 376–379.
Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG and Baylin SB . (2002). Nat. Genet., 31, 141–149.
Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Dong Chen W, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG and Baylin SB . (2004). Nat. Genet., 36, 417–422.
Taketo MM . (2004). Nat. Genet., 36, 320–322.
Veeman MT, Axelrod JD and Moon RT . (2003). Dev. Cell, 5, 367–377.
Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R, Rosenthal A and Pilarsky C . (2003). J. Pathol., 201, 204–212.
You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F and Jablons DM . (2004). Cancer Res., 64, 5385–5389.
Acknowledgements
This work was supported by the Larry Hall memorial trust and the Kazan, McClain, Edises, Abrams, Fernandez, Lyons & Farrise Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
He, B., Reguart, N., You, L. et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 24, 3054–3058 (2005). https://doi.org/10.1038/sj.onc.1208511
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208511
Keywords
This article is cited by
-
2,4-Dipropylphloroglucinol inhibits the growth of human lung and colorectal cancer cells through induction of apoptosis
Medical Oncology (2023)
-
Wnt/β-catenin signaling in cancers and targeted therapies
Signal Transduction and Targeted Therapy (2021)
-
Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex
Experimental & Molecular Medicine (2020)
-
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Scientific Reports (2018)
-
WNT signaling in glioblastoma and therapeutic opportunities
Laboratory Investigation (2016)